Patents by Inventor Yaqub Hanna
Yaqub Hanna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959097Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.Type: GrantFiled: July 27, 2023Date of Patent: April 16, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Yaqub Hanna, Sergey Viukov, Emilie Wildschutz, Noa Novershtern, Carine Joubran, Segev Naveh Tassa, Alejandro Castrejon Aguilera, Bernardo Oldak, Shadi Tarazi, Francesco Roncato
-
Patent number: 11920164Abstract: A culture medium is disclosed which comprises STAT3 activator, an ERK1/2 inhibitor and an Axin stabilizer, and optionally also a PKC inhibitor. Cell cultures comprising same and uses thereof are also disclosed.Type: GrantFiled: July 30, 2015Date of Patent: March 5, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Yaqub Hanna, Noa Novershtern, Yoach Rais
-
Publication number: 20240026262Abstract: Methods and devices for ex-utero mouse embryonic development are provided. Accordingly, there is provided a method of ex-utero culturing a mouse embryo at a zygote stage under conditions that allow developments of the embryo to organogenesis or any developmental stage therein-between. Also provided a fetal incubation system, and methods of using same.Type: ApplicationFiled: September 18, 2023Publication date: January 25, 2024Applicant: Yeda Research and Development Co. Ltd.Inventor: Yaqub HANNA
-
Publication number: 20240010973Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.Type: ApplicationFiled: July 27, 2023Publication date: January 11, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Yaqub HANNA, Sergey VIUKOV, Emilie WILDSCHUTZ, Noa NOVERSHTERN, Carine JOUBRAN, Segev NAVEH TASSA, Alejandro CASTREJON AGUILERA, Bernardo OLDAK, Shadi TARAZI, Francesco RONCATO
-
Patent number: 11851670Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to chimeric animals comprising reprogrammed somatic cells of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.Type: GrantFiled: June 11, 2019Date of Patent: December 26, 2023Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Bryce Woodbury Carey, Yaqub Hanna
-
Publication number: 20210363495Abstract: A culture medium comprising a WNT inhibitor, a SRC inhibitor and a protein kinase C (PKC) inhibitor is disclosed. The medium is devoid of an amount of GSK3beta inhibitor that increases beta-catenin translocation to the nucleus of a pluripotent stem cell being cultured in the culture medium. Uses thereof are also disclosed.Type: ApplicationFiled: July 22, 2021Publication date: November 25, 2021Applicant: Yeda Research and Development Co. Ltd.Inventors: Yaqub HANNA, Noa NOVERSHTERN, Tom Haim SHANI, Sergey VIUKOV, Rada MASSARWA, Jonathan BAYERL, Muneef AYYASH
-
Publication number: 20210253998Abstract: Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1/2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.Type: ApplicationFiled: December 10, 2020Publication date: August 19, 2021Applicant: Yeda Research and Development Co. Ltd.Inventors: Yaqub HANNA, Noa NOVERSHTERN, Yoach RAIS
-
Patent number: 10920192Abstract: Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1/2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.Type: GrantFiled: April 23, 2014Date of Patent: February 16, 2021Assignee: Yeda Research and Development Co. Ltd.Inventors: Yaqub Hanna, Noa Novershtern, Yoach Rais
-
Publication number: 20190241874Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.Type: ApplicationFiled: September 28, 2018Publication date: August 8, 2019Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
-
Patent number: 10093904Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.Type: GrantFiled: May 26, 2017Date of Patent: October 9, 2018Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
-
Publication number: 20170342386Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.Type: ApplicationFiled: May 26, 2017Publication date: November 30, 2017Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
-
Publication number: 20170275593Abstract: A culture medium is disclosed which comprises STAT3 activator, an ERK1/2 inhibitor and an Axin stabilizer, and optionally also a PKC inhibitor. Cell cultures comprising same and uses thereof are also disclosed.Type: ApplicationFiled: July 30, 2015Publication date: September 28, 2017Applicant: Yeda Research and Development Co. Ltd.Inventors: Yaqub HANNA, Noa NOVERSHTERN, Yoach RAIS
-
Patent number: 9714414Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.Type: GrantFiled: August 29, 2014Date of Patent: July 25, 2017Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
-
Patent number: 9382515Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.Type: GrantFiled: April 7, 2008Date of Patent: July 5, 2016Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
-
Publication number: 20150118755Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.Type: ApplicationFiled: August 29, 2014Publication date: April 30, 2015Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
-
Publication number: 20140315301Abstract: Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1/2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.Type: ApplicationFiled: April 23, 2014Publication date: October 23, 2014Applicant: Yeda Research and Development Co. Ltd.Inventors: Yaqub HANNA, Noa Novershtern, Yoach Rais
-
Publication number: 20110088107Abstract: The invention provides compositions and methods useful for deriving or culturing vertebrate ES cells. Certain inventive methods comprise deriving or culturing vertebrate ES cells using medium that comprises a compound that replaces Klf4 or c-Myc in generating iPS cells. The invention provides NOD ES cells and methods of deriving or culturing them.Type: ApplicationFiled: April 26, 2010Publication date: April 14, 2011Inventors: Yaqub Hanna, Rudolf Jaenisch